SPLENDRIS Trademark

Trademark Overview

On Tuesday, May 7, 2013, a trademark application was filed for SPLENDRIS with the United States Patent and Trademark Office. The USPTO has given the SPLENDRIS trademark a serial number of 79136686. The federal status of this trademark filing is IR CANCELLED - US REGISTRATION CANCELLED as of Sunday, May 7, 2023. This trademark is owned by SHENZHEN SALUBRIS; PHARMACEUTICALS CO.,LTD.. The SPLENDRIS trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations, for treating diseases of cardiovascular system, for use in haematology, dermatology, ophthalmology and gastroenterology, anti-infectives, antitumor drugs, for treating metabolic diseases, for treating nervous system diseases, for treating diseases of respiratory system, digestive system, endocrine system and immune system, for treating hypersensitivity diseases and for treating musculo-skeletal disorders; Chemico-pharmaceutical preparations, for the prevention and treatment of disorders of the nervous system, the immune system, the cardiovascular system, the metabolic system, the respiratory system, the musculo-skeletal system, digestive system and endocrine system, for the treatment of infective diseases, for use in dermatology, oncology, hematology and in tissue and organ transplantation, in ophthalmology and for treating hypersensitivity diseases; Chemical preparations for pharmaceutical purposes, for treating diseases of cardiovascular system, for use i...
splendris

General Information

Serial Number79136686
Word MarkSPLENDRIS
Filing DateTuesday, May 7, 2013
Status404 - IR CANCELLED - US REGISTRATION CANCELLED
Status DateSunday, May 7, 2023
Registration Number4642937
Registration DateTuesday, November 25, 2014
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, September 9, 2014

Trademark Statements

Goods and ServicesPharmaceutical preparations, for treating diseases of cardiovascular system, for use in haematology, dermatology, ophthalmology and gastroenterology, anti-infectives, antitumor drugs, for treating metabolic diseases, for treating nervous system diseases, for treating diseases of respiratory system, digestive system, endocrine system and immune system, for treating hypersensitivity diseases and for treating musculo-skeletal disorders; Chemico-pharmaceutical preparations, for the prevention and treatment of disorders of the nervous system, the immune system, the cardiovascular system, the metabolic system, the respiratory system, the musculo-skeletal system, digestive system and endocrine system, for the treatment of infective diseases, for use in dermatology, oncology, hematology and in tissue and organ transplantation, in ophthalmology and for treating hypersensitivity diseases; Chemical preparations for pharmaceutical purposes, for treating diseases of cardiovascular system, for use in haematology, dermatology, ophthalmology and gastroenterology, anti-infectives, antitumor drugs, for treating metabolic diseases, for treating nervous system diseases, for treating diseases of respiratory system, digestive system, endocrine system and immune system, for treating hypersensitivity diseases and for treating musculo-skeletal disorders; Medicines for human purposes, for treating diseases of cardiovascular system, for use in haematology, dermatology, ophthalmology and gastroenterology, anti-infectives, antitumor drugs, for treating metabolic diseases, for treating nervous system diseases, for treating diseases of respiratory system, digestive system, endocrine system and immune system, for treating hypersensitivity diseases and for treating musculo-skeletal disorders; Medicated troches, for the prevention and treatment of disorders of the nervous system, the immune system, the cardiovascular system, the metabolic system, the respiratory system, the musculo-skeletal system, digestive system, and endocrine system, for the treatment of infective diseases, for use in dermatology, oncology, hematology and in tissue and organ transplantation, in ophthalmology and for gastroenterological disorders; Active pharmaceutical ingredients in the nature of pharmaceutical preparations, which are used for the prevention and treatment of disorders of the nervous system, the immune system, the cardiovascular system, the metabolic system, the respiratory system, the musculo-skeletal system, digestive system, and endocrine system, for the treatment of infective diseases, for use in dermatology, oncology, hematology and in tissue and organ transplantation, in ophthalmology and for gastroenterological disorders; Prepared Chinese medicines, for treating diseases of cardiovascular system, for use in haematology, dermatology, ophthalmology and gastroenterology, anti-infectives, antitumor drugs, for treating metabolic diseases, for treating nervous system diseases, for treating diseases of respiratory system, digestive system, endocrine system and immune system, for treating hypersensitivity diseases and for treating musculo-skeletal disorders; Biochemical medicines, for treating diseases of cardiovascular system, for use in haematology, dermatology, ophthalmology and gastroenterology, anti-infectives, antitumor drugs, for treating metabolic diseases, for treating nervous system diseases, for treating diseases of respiratory system, digestive system, endocrine system and immune system, for treating hypersensitivity diseases and for treating musculo-skeletal disorders; Dietetic substances adapted for medical use, namely, beverages or food in the nature of vitamin, protein, minerals, lecithin, glucose, amino acid, folic acid, fruit juice, fruit oil, honey, seaweed glue, fish oil, cod-liver oil, cubilose, and mineral food-supplements, which are used for treating diseases of cardiovascular system, for use in haematology, dermatology, ophthalmology and gastroenterology, anti-infectives, antitumor drugs, for treating metabolic diseases, for treating nervous system diseases, for treating diseases of respiratory system, digestive system, endocrine system and immune system for treating hypersensitivity diseases and for treating musculo-skeletal disorders; Drugs for medical purposes, namely, medicines for the prevention and treatment of disorders of the nervous system, the immune system, the cardiovascular system, the metabolic system, the respiratory system, the musculo-skeletal system, digestive system, and endocrine system, for the treatment of infective diseases, for use in dermatology, oncology, hematology and in tissue and organ transplantation, in ophthalmology and for gastroenterological disorders

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status CodeF - NOT AVAILABLE
Class Status DateFriday, June 11, 2021
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameSHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD.
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
Address518040 Shenzhen, Guangdong
CN
Party NameSHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
Address518040 Shenzhen, Guangdong
CN
Party NameSHENZHEN SALUBRIS; PHARMACEUTICALS CO.,LTD.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
Address518040 Shenzhen, Guangdong
CN

Trademark Events

Event DateEvent Description
Sunday, November 26, 2023NOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG E-MAILED
Sunday, November 26, 2023DEATH OF INTERNATIONAL REGISTRATION
Monday, July 11, 2022TOTAL INVALIDATION PROCESSED BY THE IB
Thursday, June 9, 2022GENERIC MADRID TRANSACTION SENT TO IB
Wednesday, June 8, 2022GENERIC MADRID TRANSACTION CREATED
Friday, February 11, 2022TOTAL INVALIDATION OF REG EXT PROTECTION CREATED
Friday, June 11, 2021CANCELLED SECTION 71
Monday, November 25, 2019COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
Wednesday, October 9, 2019CORRECTION FROM THE IB EXAMINED, NO ACTION IS NEEDED
Friday, July 5, 2019CORRECTION TRANSACTION RECEIVED FROM IB
Thursday, July 4, 2019NEW REPRESENTATIVE AT IB RECEIVED
Friday, December 7, 2018NEW REPRESENTATIVE AT IB RECEIVED
Friday, May 8, 2015FINAL DECISION TRANSACTION PROCESSED BY IB
Monday, April 20, 2015FINAL DISPOSITION NOTICE SENT TO IB
Monday, April 20, 2015FINAL DISPOSITION PROCESSED
Thursday, March 12, 2015TEAS CHANGE OF CORRESPONDENCE RECEIVED
Wednesday, February 25, 2015FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Tuesday, November 25, 2014REGISTERED-PRINCIPAL REGISTER
Tuesday, September 9, 2014OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, September 9, 2014PUBLISHED FOR OPPOSITION
Wednesday, August 20, 2014NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Thursday, August 7, 2014NEW REPRESENTATIVE AT IB RECEIVED
Tuesday, August 5, 2014LAW OFFICE PUBLICATION REVIEW COMPLETED
Tuesday, August 5, 2014ASSIGNED TO LIE
Sunday, July 27, 2014APPROVED FOR PUB - PRINCIPAL REGISTER
Sunday, July 27, 2014EXAMINER'S AMENDMENT ENTERED
Sunday, July 27, 2014NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Sunday, July 27, 2014EXAMINERS AMENDMENT E-MAILED
Sunday, July 27, 2014EXAMINERS AMENDMENT -WRITTEN
Wednesday, June 11, 2014TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, June 11, 2014CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, June 11, 2014TEAS REQUEST FOR RECONSIDERATION RECEIVED
Tuesday, December 17, 2013FINAL REFUSAL MAILED
Monday, December 16, 2013FINAL REFUSAL WRITTEN
Wednesday, November 20, 2013TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, November 20, 2013CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, November 20, 2013TEAS RESPONSE TO OFFICE ACTION RECEIVED
Thursday, November 14, 2013REFUSAL PROCESSED BY IB
Wednesday, October 23, 2013NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Tuesday, October 22, 2013REFUSAL PROCESSED BY MPU
Monday, October 21, 2013NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Sunday, October 20, 2013NON-FINAL ACTION WRITTEN
Wednesday, October 16, 2013APPLICATION FILING RECEIPT MAILED
Sunday, October 13, 2013ASSIGNED TO EXAMINER
Saturday, October 12, 2013NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, October 10, 2013SN ASSIGNED FOR SECT 66A APPL FROM IB

Related Keywords

splendris system treating diseases pharmaceutical cardiovascular preparations immune endocrine hypersensitivity respiratory